TriSalus Life Sciences Management
Management criteria checks 1/4
TriSalus Life Sciences' CEO is Mary Szela, appointed in Jan 2018, has a tenure of 8.08 years. total yearly compensation is $4.14M, comprised of 14.5% salary and 85.5% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $1.57M. The average tenure of the management team and the board of directors is 2.4 years and 2.5 years respectively.
Key information
Mary Szela
Chief executive officer
US$4.1m
Total compensation
| CEO salary percentage | 14.54% |
| CEO tenure | 8.1yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.4yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops and commercializes pressure enabled drug delivery technologies and catheters used in interventional procedures for solid tumors and other vascular conditions. What are the underlying business or industry changes driving this perspective?TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
Mar 30TriSalus Life Sciences: Falling Despite Moving Forward Into The Market
Jun 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$71m |
| Jun 30 2025 | n/a | n/a | -US$33m |
| Mar 31 2025 | n/a | n/a | -US$30m |
| Dec 31 2024 | US$4m | US$601k | -US$33m |
| Sep 30 2024 | n/a | n/a | -US$59m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$68m |
| Dec 31 2023 | US$3m | US$518k | -US$64m |
| Sep 30 2023 | n/a | n/a | -US$53m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$861k | US$464k | -US$50m |
Compensation vs Market: Mary's total compensation ($USD4.14M) is above average for companies of similar size in the US market ($USD1.47M).
Compensation vs Earnings: Mary's compensation has increased whilst the company is unprofitable.
CEO
Mary Szela (61 yo)
Ms. Mary T. Szela, M.B.A. B.S.N., serves as Independent Director at Averin Capital Acquisition Corp. since February 2026. She is Director of Absci Corporation from July 2025. She is Director of LARONDE, In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.1yrs | US$4.14m | 0.53% $ 1.6m | |
| Chief of Clinical Strategy & Operations | 2.4yrs | US$1.38m | 0.044% $ 130.5k | |
| Chief Financial Officer | less than a year | no data | 0.45% $ 1.3m | |
| Vice President of Operations | no data | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Chief Regulatory Officer | 4.9yrs | US$652.03k | 0.089% $ 265.0k | |
| Chief Commercial Officer | 1.1yrs | no data | 0.039% $ 115.5k | |
| Chief of Research | no data | no data | 0.17% $ 511.2k | |
| Secretary & Treasurer | 2.5yrs | no data | 0.091% $ 271.2k | |
| Medical Director | 1.1yrs | no data | no data |
Experienced Management: TLSI's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.1yrs | US$4.14m | 0.53% $ 1.6m | |
| Independent Director | 2.5yrs | US$166.25k | 1.64% $ 4.9m | |
| Independent Director | 2.5yrs | US$163.75k | 1.56% $ 4.7m | |
| Independent Chairman | 9.3yrs | US$243.75k | 2.7% $ 8.1m | |
| Director | no data | no data | 0.14% $ 411.7k | |
| Independent Director | 1.1yrs | no data | 0.051% $ 152.1k | |
| Independent Director | 1.1yrs | no data | 0.016% $ 48.7k |
Experienced Board: TLSI's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/24 16:50 |
| End of Day Share Price | 2026/02/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TriSalus Life Sciences, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Justin Walsh | JonesTrading Institutional Services, LLC |